// App-Quantinova.ai

: Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification.

Researchers

Presenter

  • Paul L. Nguyen

Principal Investigators

  • Jingbin Zhang

  • Kasra Yousefi

  • Elai Davicioni

  • Robert Benjamin Den

  • Felix Y Feng

  • Daniel Eidelberg Spratt

Medical Centers

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • GenomeDx Biosciences Inc., Vancouver, BC, Canada

  • Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA

  • University of California, San Francisco, San Francisco, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Canada

Companies

  • GenomeDx Biosciences

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved